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Abstract—Automated methods for Alzheimer’s disease (AD)
classification have the potential for great clinical benefits and
may provide insight for combating the disease. Machine learning,
and more specifically deep neural networks, have been shown
to have great efficacy in this domain. These algorithms often
use neurological imaging data such as MRI and PET, but a
comprehensive and balanced comparison of these modalities has
not been performed. In order to accurately determine the relative
strength of each imaging variant, this work performs a compar-
ison study in the context of Alzheimer’s dementia classification
using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)1
dataset. Furthermore, this work analyzes the benefits of using
both modalities in a fusion setting and discusses how these data
types may be leveraged in future AD studies using deep learning.
Index Terms—Alzheimer’s disease, computer aided diagnosis,
convolutional neural network, multimodal, data fusion.
I. INTRODUCTION
ALZHEIMER’S disease (AD) is a neurodegenerative dis-order characterized by cognitive decline and dementia.
The number of individuals living with AD in the United States
is expected to reach 10 million by the year 2025 [1]. As a
result, automated methods for computer aided diagnosis could
greatly improve the ability to screen at-risk individuals.
Such methods typically take as input patient data including
demographics, medical history, genetic sequencing, and neu-
rological images among others. The resulting output is health
status indicated by a diagnosis label, which may also include
a probabilistic uncertainty on the prediction. This particular
investigation will focus on two different neuroimaging modali-
ties: structural T1-weighted MRI and AV-45 amyloid PET. The
primary goal of the investigation is to compare the efficacy of
each of these modalities in isolation as well as when both are
used as simultaneous input to a fusion system.
The algorithmic design of these methods can vary, but recent
successes in machine learning have opened the floodgates
for a plethora of deep neural networks trained for computer
1Data used in preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As
such, the investigators within the ADNI contributed to the design and
implementation of ADNI and/or provided data but did not participate in
analysis or writing of this report. A complete listing of ADNI investigators
can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/
ADNI_Acknowledgement_List.pdf
aided diagnosis. Given the visual nature of the input data, this
work opted to apply a model well suited for computer vision
tasks: the convolutional neural network (CNN). The following
sections will focus on related approaches to the AD classi-
fication problem, the methodology of both the network and
data processing pipeline, and a discussion of the classification
results.
II. RELATED WORK
Computer aided diagnosis methods in this domain have
spanned the gamut of algorithmic design. Earlier methods
often applied linear classifiers like support vector machines
(SVM) to hand-crafted biological features [2]. These features
can be defined at the individual voxel level, as in the case
for tissue probability maps, or at the regional level, including
cortical thickness and hippocampal shape or volume. The 2011
comparison performed in [2] found that whole brain methods
generally achieved higher classification accuracy than their
region-based counterparts. Additionally, there was evidence to
suggest that certain data pre-processing methods, namely the
DARTEL registration package [3], can substantially impact
classification results. These two findings informed the decision
to use whole brain volumes in this work and design a robust
registration pipeline before the classification algorithm.
Similar linear classifier or SVM-based methods exist that
align with these ideas. In [4], gray matter tissue maps were
classified with an SVM. A more complex scheme exists in
[5], where template selection was performed on gray matter
density maps and these features were clustered in preparation
for SVM classification. As previously discussed, regional
features can also be used as input to an SVM, such as spherical
harmonic coefficients calculated from the hippocampus [6].
In [7], the analysis is extended to other linear classifiers,
primarily comparing the performance between SVMs and
variations of random forest classifiers on a large conglomerate
of Alzheimer’s datasets. These models can also extend to
multiple data modalities as in [8], where features from MRI
and PET data were extracted and combined with a kernel-
based approach. In [9], the procedure was modified with
a custom loss function in order to perform both diagnosis
classification and cognitive score regression simultaneously
using a modified support vector-based model trained with
MRI, PET, and cerebrospinal fluid (CSF) images.
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2Despite the initial popularity of SVMs and linear classifiers,
there has been a transition in the last several years toward more
non-linear approaches. Namely, the introduction of artificial
neural networks has transformed the landscape of automated
Alzheimer’s dementia diagnosis. However, even these methods
have varied in construction. The works in [10, 11] used a deep
Boltzmann machine (DBM) to extract features from MRI and
PET data which are then classified using an SVM. Similarly, a
DBM was also used in [12] to extract features from MRI and
PET, but additionally included CSF and cognitive test scores.
The features are still classified with an SVM. A more standard
fully-connected neural network was trained on MRI images
in [13], but performance was improved by adding spatial
neighborhood regularization similar to the receptive field of
convolutional kernels.
This leads to the current preferred machine learning model,
the CNN. These models are well suited to tasks with 2D
or 3D data due to the shared filter weights within each
convolutional layer. A CNN was proposed in [14] that takes
fMRI slices as input to a modified LeNet-5 CNN architecture
[15]. The DeepAD paper [16] further developed this notion
by utilizing the more complex GoogleNet CNN [17]. In [18],
MRI and PET data were used to train a multimodal CNN for
classification, but it also allowed for missing modalities and
modality completion. Some methods opted to use autoencoders
[19] which can employ convolutional filters, but structurally
differ from CNNs. While CNNs are trained to map input
images to some given representation, autoencoders are trained
to perform dimensionality reduction and reconstruct the input
image. In this manner, the features learned in the middle
layer of an autoencoder can be extracted and classified with
either linear or non-linear methods. In [20], features from MRI
and PET images were extracted using a stacked autoencoder
which were then classified with softmax regression. On the
other hand, the work in [21] used an autoencoder on 2D
MRI slices to learn basis features that are then used as
CNN filters. A similar procedure was performed in [22] that
compared the performance between both 2D and 3D systems.
An autoencoder was used in [23] on full 3D MRI images to
pre-train the layers of a CNN model, and this was expanded
in [24] to include the PET modality.
Fundamentally, while methods exist that take advantage of
multiple data types and apply state-of-the-art neural network
architectures, comparison studies between modalities and ar-
chitectures have been haphazard in their use of datasets and
lacking in explanations of model efficacy. In some instances,
subsets of larger databases were used without explanations of
why certain images were included or excluded. Additionally,
pre-processing pipelines differ between these various studies.
Both of these factors contribute to incongruous modality com-
parison results between papers. Furthermore, the biological
explanations for such discrepancies are often lacking or non-
existent. This work is novel in both of these respects. First,
the pre-processing used in this work is clearly explained and
the rationale for each step is provided. Second, the modality
comparison results are discussed within a biological context
that more effectively describes the relative performance of
each data type.
III. METHODOLOGY
As previously alluded to in the discussion of related work,
pre-processing operations can have a major impact on final
classification performance. As a result, a pipeline was devel-
oped to correct several of the biases inherent in the imaging
data. While the components of the pipeline employ existing
algorithms, the overall structure differs from previous work
and allows for a more fair comparison between the MRI and
PET modalities.
This section also discusses the neural network architecture.
The design of the network is similar to the CNN-based
approaches discussed previously. Again, because the primary
goal of the investigation is a comparison of data modalities
rather than network styles, the CNN was designed to be
representative of comparable methods comprised of standard
network layers.
A. Pre-processing
The pre-processing pipeline aimed to correct several biases
that can exist in raw MRI and PET data. This also removes the
additional burden of the network learning methods to correct
or overlook these biases. Instead, the network has the isolated
task of finding patterns between healthy and Alzheimer’s
patients. The vast majority of related work also employs
similar pre-processing techniques in order to combat standard
problems; namely, most methods perform some kind of MRI
bias field correction, volumetric skull stripping, and affine
registration. This approach is nascent in its registration scheme
in order to prepare data for longitudinal studies in addition to
traditional single time instance analyses. This manifests itself
in two ways. First, our current investigation that treats each of
these scanning instances as distinct samples in the dataset is
less biased by differences in pre-processing for each modality.
Second, when the scanning instances are viewed jointly as a
single sample in the dataset for a longitudinal study, the images
are normalized both within the subject and among all subjects
in the set. Future longitudinal studies that take advantage of
this processed data will be discussed at the end of the paper.
The building blocks of the pipeline are as follows:
1) MRI Bias Field Correction: MRI images can have a low
frequency bias component as a result of transmit/receive inho-
mogeneities of the scanner [25]. This spatial non-uniformity,
while not always visually apparent, can cause problems for
image processing pipelines. As a result, many MRI processing
schemes begin by applying a bias field correction algorithm.
Non-parametric non-uniform intensity normalization (N3) [26]
is a robust and well-established approach for removing this
bias field. It optimizes for the slowly varying multiplicative
field that, when removed, restores the high frequency compo-
nents of the true signal. This work opted to employ a more
recent update to this method known as N4 [27], which makes
use of B-spline fitting for improved corrections. This step is
performed on the raw MRI images and is unnecessary for the
PET images.
2) Affine Registration: Both image modalities are regis-
tered using a linear affine transformation. Registration aims
to remove any spatial discrepancies between individuals in
3Fig. 1: Pre-processing pipeline for a single subject. A subject has N MRI scanning sessions and M PET scanning sessions;
therefore, the pipeline yields N MRI images and M PET images. The pipeline is repeated for each subject in the dataset.
the scanner, namely minor translations and rotations from a
standard orientation. Typically, scans are registered to a brain
atlas template, such as MNI152 [28]. While this procedure
is perfectly acceptable for traditional single time point analy-
ses, this pipeline was designed to accommodate longitudinal
studies as well. In such a setting, a patient in the dataset
will have multiple scanning sessions at different times, but
these images are aggregated and treated as a more complex
representation of a single data point. As a result, it is beneficial
to have congruence between the temporal scans in addition to
registration to the standard template. Consequently, MRI and
PET scans in the pipeline are registered first to an average
template created from all MRI scans from a single patient, and
then once more to the standard MNI152 space. The average
template is created by registering all scans from one patient
to a single scanning instance and then taking the mean of
these images. Therefore, each subject will have unique average
templates. Every MRI and PET scan is registered to the
respective average template before the traditional registration
with the MNI152 template. This ensures that all of the scans
are registered both temporally within each patient’s history
and generally across the entire dataset. FSL FLIRT was used
to perform the registrations [29].
3) Skull Stripping: Skull stripping is used to remove non-
brain tissue voxels from the images. This is generally framed
as a segmentation problem wherein clustering can be used to
separate the voxels accordingly, as in FSL’s brain extraction
tool (BET) [30]. However, given that the scans were already
registered to a standard space, skull stripping was a straight-
forward task. A brain mask in MNI152 space was used to zero
out any non-brain voxels in both the MRI and PET images.
Figure 1 shows the pipeline in its entirety. The process is
performed for all MRI and PET images for a single patient
in the dataset before proceeding to the next. N4 correction
is applied to all of the MRI scans before any registration
steps. All MRI scans are registered to the first scanning time
point, and the resulting images are averaged to create the
average template. The N4 corrected scans are registered to
this space before being registered with the MNI152 template.
The resulting images are then skull stripped using a binary
mask.
Amyloid PET scans were collected over 20 minutes in
dynamic list-mode 50 minutes post-injection of 370 MBq
18F-florbetapir. PET scans were attenuation corrected using a
computed tomography scan. The first 10 minutes of PET ac-
quisition was reconstruction into two 5 minute frames. Frames
were motion corrected together and referenced (normalized)
by the whole cerebellum. Each PET scan was registered to the
individual’s average T1 template with a 6 DOF registration and
then the pre-computed 12 DOF registration from average T1
to MNI152 was concatenated and applied to the PET images
to move them from native PET to MNI152 space. Finally, the
PET images were skull stripped as above.
B. Network
The CNN architecture is fairly traditional in its construction
and is most similar to that in [23]. The network takes as
input a full 3D MRI or PET image and outputs a diagnosis
label. While several processing layers exist in the network,
there are only three different varieties: convolutional layers,
max pooling layers, and fully connected layers. Convolutional
layers constitute the backbone of the CNN. As the name
suggests, 3D filters are convolved with the input to the layer.
Each kernel is made of learned weights that are shared across
4Fig. 2: Convolutional neural network for one modality. A single MRI or PET volume is taken as input, and the output is a
binary diagnosis label of either "Healthy" or "AD".
the whole input image; yet, each processing layer can have
multiple trainable kernels. This allows kernel specialization
while still affording the ability to capture variations at each
layer. Following convolutional layers, it is common to have
max pooling layers. These layers downsample an input image
by outputting the maximum response in a given region. For
example, a max pooling layer with a kernel size of 2x2x2 will
result in a output image that is half the input size in each
dimension. Each voxel in the output will correspond to the
maximum value of the input image in the associated 2x2x2
window. Fully connected layers are often placed at the end
of a CNN. These layers take the region specific convolutional
features learned earlier in the network and allow connections
between every feature. The weights in these layers are also
trainable; therefore, these layers aggregate the region features
and learn global connections between them. As a result, the
output of the final fully connected layer in the CNN is the
final diagnosis label.
Figure 2 is a diagram of the final CNN architecture for a
single modality. In this instance, the network accepts MRI or
PET images of size 182x218x182 (due to the MNI template
size), but in principle a CNN can accept an image of any size.
The image is then processed by three pairs of alternating con-
volutional (20 kernels of size 5x5x5) and max pooling layers
(kernel size 2x2x2). The convolutional layers use the ReLU
[31] activation function. Following these layers, the feature
vector is flattened before being passed as input to a fully
connected layer with 1024 nodes, a second fully connected
layer of 128 nodes, and finally a fully connected layer with
the number of diagnosis categories. In this case, there are 2
diagnosis categories corresponding to individuals with AD and
healthy controls. The two fully connected layers also use the
ReLU activation function, but the final classification is done
with the softmax function.
Figure 3 shows the extension of the network for the fusion
case. In this setting, the network takes both an MRI and PET
image of size 182x218x182 as input into parallel branches.
These branches are structured in the same manner as in the
former case, but an additional fully connected layer of 128
nodes is added at the end in order to fuse the information
from both modalities before the final classification is made.
Additionally, the number of kernels in each convolutional layer
was changed from 20 to 10 in order to keep the number of
weights in the fusion network approximately the same as in
the single modality network.
IV. EXPERIMENTAL DESIGN
Classification experiments were performed on the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
[32] database. The primary goal of ADNI has been to test
whether serial MRI, PET, other biological markers, and
clinical and neuropsychological assessment can be combined
to measure the progression of mild cognitive impairment
(MCI) and early Alzheimer’s disease. The set has clinical data
from hundreds of study participants including neuroimaging
modalities, demographics, medical history, and genetic
sequencing. This work analyzed T1-weighted MRI and
amyloid PET images in addition to the diagnosis labels given
to patients at each study visit. Neurological test scores were
examined in order to validate these labels, but were not used
during network training. Data was only used from participants
who had at least one scanning session for both MRI and
PET. Additionally, scanning sessions were not considered if
neurological testing was not performed within 2 months of
the scanning session. This was to ensure that the diagnosis
label provided during the scanning sessions had clinical
justification. As a result, a subset of 723 ADNI patients were
used. As in [16], individual scanning sessions from the same
patient were considered separately in this work. This resulted
in 1299 MRI scans, each falling into either the healthy or
AD category. Patients underwent less PET scanning, with a
total of 585 scans. Classification experiments were initially
performed using only one modality, either MRI or PET, and
using the appropriate data subset.
These sets were further split into training and testing
components in order to ascertain the generalizability of the
algorithm. When splitting the data into training and testing
subsets, scanning sessions from a single patient were not used
5Fig. 3: Convolutional neural network for fusing MRI and PET modalities. An MRI and PET scan from a single patient is
taken as input, and the output is again a binary diagnosis label.
in both the testing and training subsets. In other words, all of
a single patient’s scans were used in one of the two subsets.
This was done to ensure that the algorithm would not overfit to
the patient’s identity rather than learning the disease pattern.
In some previous works, it is unclear whether this procedure
was done. As a result, classification results in some previous
work may have been inflated by models that overfit on certain
individuals in the dataset.
Following this, fusion experiments were performed, where
an MRI and PET scan from the same individual at a given time
were used. Each scan was sent through parallel CNN branches.
At the final fully connected layer of each branch, the features
were merged into another fully connected layer that was used
to produce the classification result. These experiments used
the same number of data points as the PET experiments, albeit
with each data point having an associated MRI and PET scan.
Again, the testing and training subsets were made such that
no patient’s data was used in both subsets.
The neural network was constructed in Python using Keras
[33] as a front-end and Tensorflow [34] as the back-end
deep learning framework. The optimization procedure used
stochastic gradient descent with a learning rate of 0.0001
and a momentum of 0.9. Categorical cross-entropy was used
to classify the results of the CNN into the diagnosis labels.
Training was done on an Nvidia Titan Z GPU and took approx-
imately 20 epochs to complete each experiment. Depending
on the dataset size, epoch training times ranged between
approximately 45 minutes and 1.5 hours.
V. RESULTS AND DISCUSSION
Table I details the results of the classification experiments.
To reiterate, the structure of the MRI and PET networks are
identical, as they both take in a single volume and have the
same number of trainable weights. The fusion network takes in
two volumes, one from each modality, into parallel branches
that each have half the number of weights as a single MRI or
PET network. Aside from a few extra weights at the end of
the fusion network, the total number of weights in all three
networks is roughly the same. Additionally, the fusion network
used the same number of data points as the PET network, but
each included two volumes instead of one. The MRI network
was able to use more data points due to the larger number of
MRI scanning sessions.
Modality Accuracy
MRI 92%
PET 85%
Fusion 94%
TABLE I: Classification Accuracies
To begin, the MRI network is able to classify with 92%
accuracy. While this number is respectable, the performance
could improve beyond 95% by employing techniques such
as those described in [21–23]. However, the goal is again to
compare the performance of the data modalities in the most
balanced way possible. The inclusion of some of the more
specific techniques in [21–23], such as pre-training the CNN
filters with an autoencoder, does not enhance the modality
comparison. Rather, the added complexity may obfuscate the
findings if the pre-training effectiveness differed. As a result,
6the MRI performance of 92% is used to compare to the PET
and fusion performance.
In this vein, it can be seen that the PET network does
not perform as well as the MRI network, as it only achieves
85% accuracy. This result differs from [24], which finds very
small differences between MRI and PET versions of the same
networks. This should be expected because the authors operate
on FDG-PET, not the amyloid PET scans used in this work.
Furthermore, the accuracy of the models in [24] is noticeably
lower. Namely, the "Simple CNN" model, which is analogous
to the models used in this work, performs at 80.62% and
81.93% for MRI and FDG-PET, respectively. Then, the au-
thors’ contribution of using a stacked autoencoder along with
a CNN yielded accuracies of 85.24% and 85.53%, respectively.
This again may point to the difficulty in comparing modality
efficacies when the network structures become too complex.
Fundamentally, this investigation more clearly illustrates the
differences between the MRI and PET modalities and suggests
that the MRI modality may be more informative to machine
learning algorithms used for computer aided diagnosis.
In our experiments, the amyloid PET modality may have
performed worse due to the temporal lag of amyloid accu-
mulation and cognitive decline. In [35], the brain structure
biomarkers (e.g., FDG-PET and structural MRI) much more
closely follows the decline in cognition that a clinician uses
to diagnose Alzheimer’s dementia. Amyloid accumulation has
been hypothesized to begin more than two decades before
symptoms occur [35]. In a longitudinal study of dominantly
inherited Alzheimer’s disease [36], elevated amyloid PET sig-
nals were found 22 years before expected onset of symptoms.
Separate from the CNN pipeline, a standard method, previ-
ously described [37], was used to calculate the total amyloid
burden. Briefly, FreeSurfer [38, 39] was used to parcellate
the T1-weighted MRI scan taken closest to the amyloid PET
visit. Whole cerebellar referenced cortical regions normalized
by volume were used to calculate a single weighted standard
uptake value ratio (SUVR). The previously defined cutoff of
≥ 1.11 was used to define amyloid positivity [37].
Out of the 11 amyloid PET scans that were incorrectly
classified, 7 were controls and 4 were Alzheimer’s dementia
cases. All 7 control cases had elevated amyloid SUVR ≥
1.11 (average SUVR 1.42 ± 0.12). Two Alzheimer’s dementia
cases were amyloid positive (i.e., true misclassification) and
two Alzheimer’s cases were amyloid negative (average SUVR
0.95 ± 0.03) and therefore are unlikely to have underlying
Alzheimer’s disease neuropathology. If the 7 elevated amyloid
controls and 2 amyloid negative AD cases are removed, then
the effective PET classification accuracy rises to 97%.
The newly proposed NIA-AA research criteria for
Alzheimer’s disease [40] points out that amnestic dementia
diagnoses are not sensitive or specific for AD neuropathologic
change. From 10 to 30% of individuals classified as AD
dementia do not display AD neuropathology at autopsy [41]
and 30 to 40% of individuals classified as unimpaired healthy
have AD neuropathologic change at post-mortem examination
[42, 43]. The proposed CNN here is capturing this mismatch
between biomarker and diagnosis. The CNN labels healthy
individuals with high amyloid PET as AD and those with
Alzheimer’s dementia and low amyloid PET as non-AD. Thus,
while the phenomenon negatively impacts performance in this
context, amyloid PET scans may be adept in a longitudinal
study because elevated amyloid precedes symptom onset.
The final noteworthy result of the investigation is that the
fusion network outperformed both the individual MRI and
PET networks. Additionally, the fusion network outperformed
the MRI network despite the fact that less data points were
used. Having more PET scans available in the fusion case may
further improve the accuracy. While the fusion performance is
consistent with the results of [11, 24], this investigation more
clearly demonstrates that even the less informative modality
of PET can provide complementary information to improve
classification accuracy. It is therefore most similar to the
results of [18], but that work structures the task more as a
modality completion problem rather than the more traditional
classification task. Additionally, the work in [18] used patches
rather than total volumes. The full volume results obtained
in the traditional CNN context are more illustrative of the
phenomenon than the results of [18].
VI. CONCLUSION AND FUTURE WORK
This work compared the effectiveness of the MRI and
amyloid PET modalities in the context of computer aided
diagnosis using deep neural networks. Specifically, two iden-
tically structured CNNs were designed and trained on MRI
and amyloid PET data that were pre-processed to be as fairly
compared as possible. The classification results indicate that
MRI data is more conducive to neural network training than
amyloid PET data to predict clinical diagnosis. However,
a network that uses both modalities, even with the same
number of trainable weights, will achieve higher accuracy.
This indicates that the two data types have complementary
information that can be leveraged in these kinds of tasks.
While these results are a step forward in the optimization
of computer aided diagnosis tools for AD, the value from this
investigation must be utilized in further applications. To begin,
the efficacy of these algorithms should be examined when
the MCI state is included in classification. Following this, a
natural extension can be made to looking at AD patients on a
functional spectrum rather than distinct diagnosis categories.
Additionally, as previously alluded to, longitudinal studies that
use several scanning sessions of multiple modalities may not
only improve classification performance, but also allow the
ability to perform more complex tasks such as predicting
future cognitive decline irrespective of clinical phenotype.
These results would be invaluable to clinicians, as they can
directly inform decisions regarding preemptive or preventative
care.
ACKNOWLEDGMENT
The authors would like to thank the Integrated Data Driven
Discovery in Earth and Astrophysical Sciences (IDEAS) pro-
gram at Northwestern University (NSF Research Traineeship
Grant 1450006), the Biomedical Data Driven Discovery (BD3)
training program at Northwestern University (NIH Grant
5T32LM012203-02), and the National Institute on Aging
7(T32AG020506) for financial support. The authors would also
like to thank the QUEST High Performance Computing Clus-
ter at Northwestern University for computational resources.
Data collection and sharing for this project was funded
by the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
(National Institutes of Health Grant U01 AG024904) and DOD
ADNI (Department of Defense award number W81XWH-12-
2-0012). ADNI is funded by the National Institute on Aging,
the National Institute of Biomedical Imaging and Bioengineer-
ing, and through generous contributions from the following:
AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discov-
ery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen;
Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Ei-
sai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company;
EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated
company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO
Ltd.; Janssen Alzheimer Immunotherapy Research & Devel-
opment, LLC.; Johnson & Johnson Pharmaceutical Research
& Development LLC.; Lumosity; Lundbeck; Merck & Co.,
Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neu-
rotrack Technologies; Novartis Pharmaceuticals Corporation;
Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceu-
tical Company; and Transition Therapeutics. The Canadian
Institutes of Health Research is providing funds to support
ADNI clinical sites in Canada. Private sector contributions
are facilitated by the Foundation for the National Institutes
of Health (www.fnih.org). The grantee organization is the
Northern California Institute for Research and Education,
and the study is coordinated by the Alzheimer’s Therapeutic
Research Institute at the University of Southern California.
ADNI data are disseminated by the Laboratory for Neuro
Imaging at the University of Southern California.
REFERENCES
[1] L. Hebert, P. Scherr, J. Bienias, D. Bennett, and D. Evans, “State-specific
projections through 2025 of alzheimer disease prevalence,” Neurology,
vol. 62, no. 9, pp. 1645–1645, 2004.
[2] R. Cuingnet, E. Gerardin, J. Tessieras, G. Auzias, S. Lehéricy, M.-O.
Habert, M. Chupin, H. Benali, O. Colliot et al., “Automatic classification
of patients with alzheimer’s disease from structural mri: a comparison
of ten methods using the adni database,” NeuroImage, vol. 56, no. 2,
pp. 766–781, 2011.
[3] J. Ashburner, “A fast diffeomorphic image registration algorithm,”
NeuroImage, vol. 38, no. 1, pp. 95–113, 2007.
[4] S. Klöppel, C. M. Stonnington, C. Chu, B. Draganski, R. I. Scahill, J. D.
Rohrer, N. C. Fox, C. R. Jack Jr, J. Ashburner, and R. S. Frackowiak,
“Automatic classification of mr scans in alzheimer’s disease,” Brain, vol.
131, no. 3, pp. 681–689, 2008.
[5] M. Liu, D. Zhang, E. Adeli, and D. Shen, “Inherent structure-based mul-
tiview learning with multitemplate feature representation for alzheimer’s
disease diagnosis,” IEEE Transactions on Biomedical Engineering,
vol. 63, no. 7, pp. 1473–1482, 2016.
[6] E. Gerardin, G. Chételat, M. Chupin, R. Cuingnet, B. Desgranges, H.-S.
Kim, M. Niethammer, B. Dubois, S. Lehéricy, L. Garnero et al., “Mul-
tidimensional classification of hippocampal shape features discriminates
alzheimer’s disease and mild cognitive impairment from normal aging,”
Neuroimage, vol. 47, no. 4, pp. 1476–1486, 2009.
[7] M. R. Sabuncu, E. Konukoglu, A. D. N. Initiative et al., “Clinical
prediction from structural brain mri scans: a large-scale empirical study,”
Neuroinformatics, vol. 13, no. 1, pp. 31–46, 2015.
[8] C. Zu, B. Jie, M. Liu, S. Chen, D. Shen, D. Zhang, A. D. N. Initiative
et al., “Label-aligned multi-task feature learning for multimodal classifi-
cation of alzheimerâA˘Z´s disease and mild cognitive impairment,” Brain
imaging and behavior, vol. 10, no. 4, pp. 1148–1159, 2016.
[9] X. Zhu, H.-I. Suk, and D. Shen, “A novel matrix-similarity based
loss function for joint regression and classification in ad diagnosis,”
NeuroImage, vol. 100, pp. 91–105, 2014.
[10] H.-I. Suk and D. Shen, “Deep learning-based feature representation for
ad/mci classification,” in International Conference on Medical Image
Computing and Computer-Assisted Intervention. Springer, 2013, pp.
583–590.
[11] H.-I. Suk, S.-W. Lee, D. Shen, A. D. N. Initiative et al., “Hierarchical
feature representation and multimodal fusion with deep learning for
ad/mci diagnosis,” NeuroImage, vol. 101, pp. 569–582, 2014.
[12] F. Li, L. Tran, K.-H. Thung, S. Ji, D. Shen, and J. Li, “A robust deep
model for improved classification of ad/mci patients,” IEEE journal of
biomedical and health informatics, vol. 19, no. 5, pp. 1610–1616, 2015.
[13] X. Yang, Q. Wu, D. Hong, and J. Zou, “Spatial regularization for neural
network and application in alzheimer’s disease classification,” in Future
Technologies Conference (FTC). IEEE, 2016, pp. 831–837.
[14] S. Sarraf and G. Tofighi, “Classification of alzheimer’s disease using fmri
data and deep learning convolutional neural networks,” arXiv preprint
arXiv:1603.08631, 2016.
[15] Y. LeCun, L. Bottou, Y. Bengio, and P. Haffner, “Gradient-based learning
applied to document recognition,” Proceedings of the IEEE, vol. 86,
no. 11, pp. 2278–2324, 1998.
[16] S. Sarraf, G. Tofighi et al., “Deepad: AlzheimerâA˘š s disease classi-
fication via deep convolutional neural networks using mri and fmri,”
bioRxiv, p. 070441, 2016.
[17] C. Szegedy, W. Liu, Y. Jia, P. Sermanet, S. Reed, D. Anguelov, D. Erhan,
V. Vanhoucke, and A. Rabinovich, “Going deeper with convolutions,”
in Proceedings of the IEEE conference on computer vision and pattern
recognition, 2015, pp. 1–9.
[18] R. Li, W. Zhang, H.-I. Suk, L. Wang, J. Li, D. Shen, and S. Ji, “Deep
learning based imaging data completion for improved brain disease
diagnosis,” in International Conference on Medical Image Computing
and Computer-Assisted Intervention. Springer, 2014, pp. 305–312.
[19] G. E. Hinton and R. S. Zemel, “Autoencoders, minimum description
length and helmholtz free energy,” in Advances in neural information
processing systems, 1994, pp. 3–10.
[20] S. Liu, S. Liu, W. Cai, H. Che, S. Pujol, R. Kikinis, D. Feng, M. J.
Fulham et al., “Multimodal neuroimaging feature learning for multiclass
diagnosis of alzheimer’s disease,” IEEE Transactions on Biomedical
Engineering, vol. 62, no. 4, pp. 1132–1140, 2015.
[21] A. Gupta, M. Ayhan, and A. Maida, “Natural image bases to represent
neuroimaging data,” in International Conference on Machine Learning,
2013, pp. 987–994.
[22] A. Payan and G. Montana, “Predicting alzheimer’s disease: a neu-
roimaging study with 3d convolutional neural networks,” arXiv preprint
arXiv:1502.02506, 2015.
[23] E. Hosseini-Asl, R. Keynton, and A. El-Baz, “Alzheimer’s disease diag-
nostics by adaptation of 3d convolutional network,” in Image Processing
(ICIP), 2016 IEEE International Conference on. IEEE, 2016, pp. 126–
130.
[24] T. D. Vu, H.-J. Yang, V. Q. Nguyen, A.-R. Oh, and M.-S. Kim,
“Multimodal learning using convolution neural network and sparse
autoencoder,” in Big Data and Smart Computing (BigComp), 2017 IEEE
International Conference on. IEEE, 2017, pp. 309–312.
[25] E. McVeigh, M. Bronskill, and R. Henkelman, “Phase and sensitivity of
receiver coils in magnetic resonance imaging,” Medical physics, vol. 13,
no. 6, pp. 806–814, 1986.
[26] J. G. Sled, A. P. Zijdenbos, and A. C. Evans, “A nonparametric method
for automatic correction of intensity nonuniformity in mri data,” IEEE
transactions on medical imaging, vol. 17, no. 1, pp. 87–97, 1998.
[27] N. J. Tustison, B. B. Avants, P. A. Cook, Y. Zheng, A. Egan, P. A.
Yushkevich, and J. C. Gee, “N4itk: improved n3 bias correction,” IEEE
transactions on medical imaging, vol. 29, no. 6, pp. 1310–1320, 2010.
[28] V. Fonov, A. C. Evans, K. Botteron, C. R. Almli, R. C. McKinstry,
D. L. Collins, B. D. C. Group et al., “Unbiased average age-appropriate
atlases for pediatric studies,” Neuroimage, vol. 54, no. 1, pp. 313–327,
2011.
[29] M. Jenkinson, P. Bannister, M. Brady, and S. Smith, “Improved op-
timization for the robust and accurate linear registration and motion
correction of brain images,” Neuroimage, vol. 17, no. 2, pp. 825–841,
2002.
[30] S. M. Smith, “Fast robust automated brain extraction,” Human brain
mapping, vol. 17, no. 3, pp. 143–155, 2002.
[31] R. H. Hahnloser, R. Sarpeshkar, M. A. Mahowald, R. J. Douglas, and
H. S. Seung, “Digital selection and analogue amplification coexist in a
cortex-inspired silicon circuit,” Nature, vol. 405, no. 6789, pp. 947–951,
2000.
8[32] C. R. Jack, M. A. Bernstein, N. C. Fox, P. Thompson, G. Alexander,
D. Harvey, B. Borowski, P. J. Britson, J. L Whitwell, C. Ward et al.,
“The alzheimer’s disease neuroimaging initiative (adni): Mri methods,”
Journal of magnetic resonance imaging, vol. 27, no. 4, pp. 685–691,
2008.
[33] F. Chollet et al., “Keras,” 2015.
[34] M. Abadi, P. Barham, J. Chen, Z. Chen, A. Davis, J. Dean, M. Devin,
S. Ghemawat, G. Irving, M. Isard et al., “Tensorflow: a system for large-
scale machine learning.” in OSDI, vol. 16, 2016, pp. 265–283.
[35] C. R. Jack Jr, D. S. Knopman, W. J. Jagust, R. C. Petersen, M. W.
Weiner, P. S. Aisen, L. M. Shaw, P. Vemuri, H. J. Wiste, S. D. Weigand
et al., “Tracking pathophysiological processes in alzheimer’s disease:
an updated hypothetical model of dynamic biomarkers,” The Lancet
Neurology, vol. 12, no. 2, pp. 207–216, 2013.
[36] B. A. Gordon, T. M. Blazey, Y. Su, A. Hari-Raj, A. Dincer, S. Flores,
J. Christensen, E. McDade, G. Wang, C. Xiong et al., “Spatial patterns
of neuroimaging biomarker change in individuals from families with
autosomal dominant alzheimer’s disease: a longitudinal study,” The
Lancet Neurology, vol. 17, no. 3, pp. 241–250, 2018.
[37] S. M. Landau, M. A. Mintun, A. D. Joshi, R. A. Koeppe, R. C. Petersen,
P. S. Aisen, M. W. Weiner, W. J. Jagust, and A. D. N. Initiative, “Amy-
loid deposition, hypometabolism, and longitudinal cognitive decline,”
Annals of neurology, vol. 72, no. 4, pp. 578–586, 2012.
[38] B. Fischl, “Freesurfer,” Neuroimage, vol. 62, no. 2, pp. 774–781, 2012.
[39] B. Fischl, A. Liu, and A. M. Dale, “Automated manifold surgery:
constructing geometrically accurate and topologically correct models
of the human cerebral cortex,” IEEE transactions on medical imaging,
vol. 20, no. 1, pp. 70–80, 2001.
[40] C. R. Jack, D. A. Bennett, K. Blennow, M. C. Carrillo, B. Dunn,
S. B. Haeberlein, D. M. Holtzman, W. Jagust, F. Jessen, J. Karlawish
et al., “Nia-aa research framework: Toward a biological definition of
alzheimer’s disease,” Alzheimer’s & Dementia, vol. 14, no. 4, pp. 535–
562, 2018.
[41] P. T. Nelson, E. Head, F. A. Schmitt, P. R. Davis, J. H. Neltner, G. A.
Jicha, E. L. Abner, C. D. Smith, L. J. Van Eldik, R. J. Kryscio et al.,
“AlzheimerâA˘Z´s disease is not âA˘IJbrain agingâA˘I˙: neuropathological,
genetic, and epidemiological human studies,” Acta neuropathologica,
vol. 121, no. 5, pp. 571–587, 2011.
[42] D. Bennett, J. Schneider, Z. Arvanitakis, J. Kelly, N. Aggarwal, R. Shah,
and R. Wilson, “Neuropathology of older persons without cognitive
impairment from two community-based studies,” Neurology, vol. 66,
no. 12, pp. 1837–1844, 2006.
[43] J. L. Price, P. Davis, J. Morris, and D. White, “The distribution of
tangles, plaques and related immunohistochemical markers in healthy
aging and alzheimer’s disease,” Neurobiology of aging, vol. 12, no. 4,
pp. 295–312, 1991.
